Modality
Nanobody
MOA
HER2
Target
SHP2
Pathway
PI3K/AKT
CMLACCWet AMD
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Mar 2029
Phase 2Current
NCT04418605
2,165 pts·Wet AMD
2018-09→2029-03·Not yet recruiting
NCT03837996
1,083 pts·ACC
2018-04→2028-10·Not yet recruiting
3,248 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-10-032.5y awayPh2 Data· ACC
2029-03-183.0y awayPh2 Data· Wet AMD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2
Not yet…
P2
Not yet…
Catalysts
Ph2 Data
2028-10-03 · 2.5y away
ACC
Ph2 Data
2029-03-18 · 3.0y away
Wet AMD
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04418605 | Phase 2 | Wet AMD | Not yet recr... | 2165 | PANSS |
| NCT03837996 | Phase 2 | ACC | Not yet recr... | 1083 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP |